Invention:
The invention is a preclinical drug candidate (HCV3) based on the discovery that substituted 1-arylalkyl-4-acylaminopiperide compounds have shown to be effective antagonists of mu-, delta-, and kappa-opioid receptors and/or alpha-2-adrenoreceptors. HCV3 can be used to treat clinical conditions that are due to activation of any one or more of the receptors, including hemorrhagic shock, nicotine withdrawal symptoms, gastrointestinal side effects of opioids, cancer therapy, epithelial wounds, herpes zoster infection, opioid-induced pruritus, as well as other clinical conditions.
Background:
Currently, traditional narcotic analgesics are employed to manage pain and induce anesthesia, but they come with the drawback of potential overdose complications and the risk of patient intolerance. The innovation lies in its ability to counteract the effects of narcotic substances while minimizing toxic actions, offering a safer and more comprehensive solution compared to current technologies, thereby addressing critical gaps and improving overall patient outcomes.
Applications:
- Pain management
- Addiction treatment
- Narcotic alternative
Advantages:
- Minimized dependence and tolerance
- Safer alternative
Status: Issued patent # 11,440,885
